Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations

Annals of Thoracic Surgery

Volumn 66, Issue 2, 1998, Pages 535-540

  Miller, Bruce E ^a   Tosone, Steven R ^a   Tam, Vincent K H ^b   Kanter, Kirk R ^b   Guzzetta, Nina A ^a   Bailey, James M ^a   Levy, Jerrold H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; PROTAMINE SULFATE;

ADOLESCENT; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; REOPERATION; THORAX DRAINAGE;

ADOLESCENT; APROTININ; BLOOD COAGULATION DISORDERS; BLOOD COMPONENT TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; FIBRINOGEN; HEMOSTATICS; HUMANS; LENGTH OF STAY; PLATELET COUNT; PROSPECTIVE STUDIES; REOPERATION; THROMBELASTOGRAPHY; TREATMENT OUTCOME;

EID: 0031663326     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00469-X     Document Type: Article

References (23)

1. Royston D., Taylor K.M., Bidstrup B.P., Sapsford R.N. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 2:1987;1289-1291.
2. Van Oeveren W., Jansen N.J.G., Bidstrup B.P., et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg. 44:1987;640-645.
3. Dietrich W., Spannagl M., Jochum M., et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology. 73:1990;1119-1126.
4. Murkin J.M., Lux J., Shannon N.A., et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 107:1994;554-561.
5. Bidstrup B.P., Royston D., Sapsford R.N., Taylor K.M. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 97:1989;364-372.
6. Levy J.H., Pifarre R., Schaff H.V., et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
7. Dietrich W., Mossinger H., Spannagl M., et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 105:1993;712-720.
8. Huang H., Ding W., Su Z., Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg. 106:1993;11-18.
9. Herynkopf F., Lucchese F., Pereira E., Kalil R., Prates P., Nesralla I.A. Aprotinin in children undergoing correction of congenital heart defects a double-blind pilot study . J Thorac Cardiovasc Surg. 108:1994;517-521.
10. D'Errico C.C., Shayevitz J.R., Martindale S.J., Mosca R.S., Bove E.L. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg. 83:1996;1193-1199.
11. Boldt J., Knothe C., Zickmann B., Wege N., Dapper F., Hempelmann G. Aprotinin in pediatric cardiac operations platelet function, blood loss, and use of homologous blood . Ann Thorac Surg. 55:1993;1460-1466.
12. Boldt J., Knothe C., Zickmann B., Wege N., Dapper F., Hempelmann G. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations influence on platelet function and blood loss . J Thorac Cardiovasc Surg. 105:1993;705-711.
13. Levy J.H., Bailey J.M., Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 80:1994;1013-1018.
14. Davies M.J., Allen A., Kort H., et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg. 63:1997;497-503.
15. Tuman K.J., Spiess B.D., McCarthy R.J., Ivankovich A.D. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg. 69:1989;69-75.
16. Spiess B.D., Soltow L., Dobbyn R., Chandler W.L. The effects of cardiopulmonary bypass on shear modulus in a clinical series of cardiopulmonary bypass patients as measured by thromboelastography [Abstract]. Anesthesiology. 81:1994;A566.
17. Miller B.E., Mochizuki T., Levy J.H., et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg. 85:1997;1196-1202.
18. Chan A.K.C., Leaker M., Burrows F.A., et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 77:1997;270-277.
19. Harker L.A., Malpass T.W., Branson H.E., Hessel E.A. II, Slichter S.J. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass acquired transient platelet dysfunction associated with selective α-granule release . Blood. 56:1980;824-834.
20. Gralnick H.R., Fischer R.D. The hemostatic response to open-heart operations. J Thorac Cardiovasc Surg. 61:1971;909-915.
21. Sundt T.M. III, Kouchoukos N.T., Saffitz J.E., Murphy S.F., Wareing T.H., Stahl D.J. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg. 55:1993;1418-1424.
22. Wachtfogel Y.T., Kucich U., Hack C.E., et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 106:1993;1-10.
23. Hill G.E., Pohorecki R., Alonso A., Rennard S.I., Robbins R.A. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 83:1996;696-700.